NCT07115368 - Study of GS-1219 in Participants With HIV-1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

September 19, 2025

Study Completion Date

October 2, 2025

Conditions

HIV-1-infection

Interventions

DRUG

GS-1219

Administered orally

DRUG

BVY

Administered orally

DRUG

Standard of Care

Antiretroviral therapy, administered orally non nonnucleoside reverse transcriptase inhibitor (NNRTIs), examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)

Trial Locations (15)

20017

Washington Health Institute, Washington D.C.

32720

Midland Florida Clinical Research Center, DeLand

32803

BLISS Health Inc, Orlando

Orlando Immunology Center, Orlando

33407

Triple O Research Institute, West Palm Beach

34982

Midway Immunology and Research Center, Ft. Pierce

48072

Be Well Medical Center, Berkley

75208

Prism Health North Texas, Dallas

75246

North Texas Infectious Diseases Consultants, Dallas

78705

Central Texas Clinical Research, Austin

79902

AXCES Research Group, El Paso

84102

AXCES Research Group, Salt Lake City

90036

Ruane Clinical Research Group, Los Angeles

90069

Mills Clinical Research, Los Angeles

94115

Quest Clinical Research, San Francisco